SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Sponsor: Icahn School of Medicine at Mount Sinai
ClinicalTrials ID:NCT06945315
This trial evaluates the impact of saline-assisted fascial engorgement (SAFE) on erectile function post-robotic-assisted radical prostatectomy (RALP). Eligible participants are men over 18, potent, sexually active, and undergoing nerve-sparing RALP. The intervention involves hydrodissection using micro-ultrasound guidance to enhance nerve preservation and optimize post-surgery erectile function recovery.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Robotic-assisted radical prostatectomy (RALP) has become the standard of care in the management of localized prostate cancer. However, post-prostatectomy erectile dysfunction (ED) and urinary incontinence still pose a challenge that adversely affects the patient's quality of life. Hydrodissection (HD) was introduced in 1987 in the medical field and it was tested for the first time during a retropubic radical prostatectomy back in 2005. Since then, research has indicated an improvement in erectile function results, presumably because of a less traumatic neural dissection and a decreased risk of neuropraxia. In an effort to achieve a balance between oncological excision and functional preservation, prostate surgery is evolving to incorporate intraoperative real-time evaluation of extracapsular extension. Recently, a micro-ultrasound operating at 29 MHz has been introduced. It provides a resolution down to 70 μ to assess the glandular pattern and cellular density of the prostatic tissue. Given the experience in more than a thousand cases with this technology, and the growing literature showing promising results in the detection and staging of prostate cancer; the researchers decided to implement this tool as guidance for hydrodissection of the layers of the lateral prostatic fascia.
Robotic-Assisted Laparoscopic Prostatectomy and SAFE (Saline assisted fascial engorgement) nerve preservation guided by Microultrasound (MUS) is a prospective randomized controlled trial designed to evaluate the impact of normal saline solution hydrodissection (HD) on erectile function outcomes after RALP. This innovative approach consists of a transrectal ultrasound-guided HD using a high-resolution Microultrasound (MUS) (ExactVu micro-ultrasound, Exact Imaging, Markham, Canada). The technique will be applied to those patients who undergo grade 1, 2, or 3 NS approach taking into account the grading system proposed by Tewari et al.
The hypothesis is that the SAFE technique could minimize the risk of a traumatic neurovascular bundle dissection while assessing the prostatic capsule integrity with a high-resolution MUS. The researchers also hypothesize that the use of SAFE along with RALP will optimize the post-surgery recovery of erectile function.
Eligibility Criteria
Inclusion Criteria
- Age > 18 years at the time of consent.
- Men who are potent (SHIM ≥ 17) and sexually active, who are planned to undergo a grade 1, 2, or 3 nerve-sparing approaches, as per the grading system during RALP.
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria
- Subjects who are candidates for salvage RALP
- Subjects on androgen deprivation therapy (ADT)
- Subjects in whom PDE5 inhibitors are contraindicated
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Mount Sinai Hospital | 10029 | New York | New York |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.